Skip to content
MS
unreviewed

Ornithine transcarbamylase (OTC)

1 reactions · 1 pathways

Cofactors used

Clinical / pharmacological. OTC deficiency (X-linked, commonest urea cycle defect): hyperammonaemia with HIGH orotic acid, low BUN

What it does, reaction by reaction

1 reactions

Urea Cycle Amino Acid & Nitrogen Metabolism · Mitochondrial matrix + cytosol

step 2 Irreversible

Carbamoyl phosphate + ornithine → citrulline + Pᵢ

Converts Carbamoyl phosphate Ornithine into Citrulline Pi

› Notes

Ornithine transcarbamylase (OTC) catalyzes this mitochondrial reaction without direct ATP use. Citrulline is exported to the cytosol in exchange for ornithine; the reaction is effectively irreversible under physiological conditions because carbamoyl phosphate is high energy.

Showing all 1 reactions.

What accelerates and inhibits it

Regulation is pathway-specific, so each context is listed separately

0 entries

No regulation recorded for this enzyme in the source documents.

Recent literature

Europe PMC · fetched just now · sorted by publication date

  1. 1
  2. 2
  3. 3
    Factors contributing to medication safety incidents observed by community pharmacists - a content analysis of incident reports.

    Lohtaja M, Schoultz A, Mönkkönen I, Holmström AR. · 2026-09-21

    open access unreviewed
  4. 4
  5. 5
    Effects of kudzu extract on alcohol consumption among men and women seeking treatment for alcohol use disorder.

    Keith DR, Liu J, Vitaliano G, Lukas SE. · 2026-09-04

    open access unreviewed
  6. 6
  7. 7
    Characterizing menstrual health and education needs among menstruating adolescents: A cross-sectional study on dysmenorrhea, cycle irregularities, and menstrual education.

    Flores-Caldera I, Morales KN, Rivera BI, Colón-Díaz M, Nieves Y, Rosado C, Martínez MF, Diaz-Betancourt A, Co… · 2026-07-27

    open access unreviewed
  8. 8
    Effects of PeptiSleep™ on sleep modification and biometrics in adults with sleep impairment: A randomised, placebo-controlled pilot study.

    Mohan NM, Keogh B, Adelfio A, Maldonado R, Rao A, Altini M, Khaldi N, Franklyn-Miller A. · 2026-07-28

    open access unreviewed
  9. 9
    Targeted delivery of mRNA to immune cells for <i>in vivo</i> cell therapy.

    Wang D, Li Y, Deng J, Li M, Wu LP. · 2026-08-12

    open access unreviewed
  10. 10
    Implantable starch-based extrudates for controlled release of corticosteroids.

    Lemos PVF, Kunert JM, Trutschel ML, Mäder K. · 2026-07-29

    open access unreviewed

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.